FCAR (JJP-1212 Biosimilar) Recombinant Monoclonal Antibody

Code CSB-RA008531MB1HU
Size US$9799
Order now
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Uniprot No.
Target Names
Alternative Names
Human IgG4k monoclonal antibody against CD89 research-grade biosimilar; JJP1212 research-grade biosimilar; JJP 1212 research-grade biosimilar ;FCAR antibody; CD89 antibody; Immunoglobulin alpha Fc receptor antibody; IgA Fc receptor antibody; CD antigen CD89 antibody
Species Reactivity
Human
Immunogen
Recombinant Human FCAR protein
Immunogen Species
Homo sapiens (Human)
Conjugate
Non-conjugated
Clonality
Monoclonal
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
0.01M PBS,pH7.4
Form
Liquid
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Notes
Validation Status
Application-specific performance (e.g., in flow cytometry, ELISA, IHC or other assay formats) has not yet been experimentally verified by CUSABIO. Users are advised to determine the optimal working conditions empirically in their own assay systems.
Guaranteed Quality
① Antibody purity > 95% tested by SDS-PAGE.
② Endotoxin level < 0.1EU/ug tested by LAL method.
Lead Time
3-4 weeks
Description

This recombinant monoclonal antibody is a research-grade biosimilar to JJP-1212, designed for research targeting FCAR (Fc fragment of IgA receptor), also known as CD89. FCAR is an immunoglobulin superfamily receptor expressed primarily on myeloid cells including neutrophils, monocytes, macrophages, and eosinophils. This receptor mediates critical immune functions by binding the Fc region of IgA antibodies, triggering phagocytosis, inflammatory mediator release, and antibody-dependent cellular cytotoxicity. FCAR plays significant roles in mucosal immunity and has been implicated in various pathological conditions including IgA nephropathy, inflammatory bowel disease, and certain autoimmune disorders. Dysregulation of FCAR signaling has also been associated with chronic inflammatory diseases and immune complex-mediated pathologies.

The reference antibody JJP-1212 has been utilized in immunological research to investigate FCAR expression patterns and functional mechanisms in immune responses. This biosimilar provides researchers with a reliable tool for studying FCAR-mediated immune processes, exploring therapeutic targets in IgA-related diseases, and investigating myeloid cell biology in both normal and disease contexts.

Usage
It is a non-therapeutic biosimilar antibody, owning the same variable region from the corresponding approved therapeutic antibody. In conclusion, it is a research-grade biosimilar antibody and expressed in mammalian cell, which can be directly used as positive controls in drug discovery or used for rapid verification of the biological functions of target protein.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Binds to the Fc region of immunoglobulins alpha. Mediates several functions including cytokine production.
Gene References into Functions
  1. FcalphaRI-induced cytokine production is orchestrated via upregulation of cytokine translation and caspase-1 activation, which is dependent on glycolytic reprogramming. PMID: 29491406
  2. In transgenic mice, IgAN pathogenesis involves impaired clearance of abnormal IgA via CD89, primarily by the Kupffer cells. Conditional IgAN progression in CD89 transgenic mice thus reveals important aspects of IgAN pathogenesis. PMID: 27437939
  3. a novel Fcar splice variant termed variant APD isolated from a healthy volunteer that lacks only the IgA-binding EC1 domain, is reported. PMID: 28103138
  4. Findings suggest a basis for the use of Fc receptor I for IgA (FcalphaRI) as a molecular target for the treatment of lupus. PMID: 25907714
  5. induces different forms of neutrophil death, depending on the inflammatory microenvironment PMID: 25339672
  6. this study examined the expression of IL-4 mRNA, IFN-c mRNA and FcaRI mRNA in tonsillar mononuclear cells of IgA nephropathy9(IgAN) patients and non-IgAN patients. PMID: 24732061
  7. FCAR polymorphism is not associated with high susceptibility to IGA nephropathy in caucasians. PMID: 21750160
  8. Abnormally glycosylated IgA1 and soluble CD89-IgA and IgA-IgG complexes, features of primary IgA nephropathy, are also present in alcoholic cirrhosis. PMID: 21866091
  9. Genetic variation at the promoter region of IgA receptor is associated with IgA nephropathy. PMID: 21273231
  10. These results suggest a role of anti-FcaRI Fab as a negative regulator in controlling the magnitude of the innate immune response PMID: 21985370
  11. Glycosylation of the CH2/CH3 interface inhibits interaction with the pathogen IgA binding protein SSL7, while maintaining binding of pIgR, essential to the biosynthesis and transport of SIgA. PMID: 21784854
  12. In this study, human mammary carcinoma cells are efficiently killed when incubated with human neutrophils and tumor-specific FcalphaRI bispecific or immunoglobulin A antibodies. PMID: 21653835
  13. Data show that the Fc(alpha)RI 844 A>G polymorphism is not associated with systemic sclerosis or rheumatoid arthritis sceptibility. PMID: 21159834
  14. FcalphaRI defines a function for pentraxins in inflammatory responses involving neutrophils and macrophages. It also highlights the innate aspect of otherwise humoral immunity-associated antibody receptors. PMID: 21383176
  15. There is an association between the levels of sCD89-IgA complexes in serum and the severity of IgA nephropathy, and a possible genetic component in regulating the production or expression of sCD89. PMID: 20811333
  16. Endocytosis of FcalphaR is clathrin- and dynamin-dependent, but is not regulated by Rab5, and the endocytic motif is not located in the cytoplasmic domain of FcalphaR. PMID: 19859085
  17. CD89 circulates in a high molecular mass form in complex covalently linked to IgA and contributes to the formation of polymeric serum IgA. PMID: 11801662
  18. study suggests that expression of the FcR splice isoform DeltaEC2 but not Delta66EC2 is differentially regulated in a cell type-specific manner and in response to inflammatory and/or infectious processes PMID: 12560105
  19. The Fc alpha receptor 5'-flanking region from -102 to -64 relative to the ATG translation initiation codon is essential for promoter activity and contains two functional binding motifs for C/EBP and Ets family members at -74 and -92, respectively. PMID: 12594283
  20. there is a bivalent, pH-dependent interaction between FcalphaRI and IgA with important implications for cytokine-dependent phagocytosis of IgA and the FcalphaRI-mediated degradation or recycling of IgA PMID: 12634059
  21. crystal structures of human FcalphaRI alone and in a complex with the Fc region of IgA1 (Fcalpha) PMID: 12768205
  22. Crystal structure of the ectodomain of human FcalphaRI PMID: 12783876
  23. expression pattern of CD89 and its signalling subunit, the FcR gamma chain, on circulating myeloid cells and in various tissues PMID: 12791088
  24. FcalphaRI expressed by interstitial-type dendritic cells could play a critical role to sample IgA-recognized antigens and also during dendritic cell activation. PMID: 15371488
  25. Pathogenic group A and group B streptococci are well known to produce virulence factors that block the binding of IgA to the leukocyte IgA receptor, Fc alphaRI, thereby inhibiting IgA-mediated immunity. PMID: 16293625
  26. Fc receptor gamma RI interacts with the unrelated immunoreceptors FcalphaRI and FcepsilonRI [FCalphaRI, also called CD89] PMID: 16627486
  27. These results indicate that GPVI is unique amongst the receptors of its family as it uses different structural domains to interact with several agonists and provide evidence that different sites on GPVI constitute targets to develop antagonists of GPVI. PMID: 16876821
  28. On monomeric targeting, FcalphaRI functions as an FcRgamma ITAM-dependent apoptotic module that may be fundamental for controlling inflammation and tumor growth. PMID: 16990604
  29. Carriers of 92Asn polymorphism in the myeloid IgA Fc receptor had increased risk of myocardial infarction in CARE and increased odds of coronary heart disease in WOSCOPS study groups. PMID: 17008591
  30. FCAR promoter SNPs may be related to chronic HCV infection and disease progression in Japanese chronic hepatitis C. PMID: 17033823
  31. Fc alpha receptor type I activation mediates glomerulonephritis progression by initiating a cytokine/chemokine cascade that promotes leukocyte recruitment and kidney damage in transgenic mice. PMID: 17393381
  32. results suggest an endogenous mechanism by which FcalphaR functionality is down-regulated in an 'allergic environment' where FcepsilonRI is co-expressed and extensively cross-linked on FcalphaR-expressing effector cells PMID: 18700185
  33. Immunoglobulin A: Fc(alpha)RI interactions induce neutrophil migration through release of leukotriene B4. PMID: 19555692
  34. Pathogen selection by bacterial decoy proteins drives FcalphaRI and IgA-Fc coevolution. PMID: 17548632

Show More

Hide All

Subcellular Location
[Isoform A.1]: Cell membrane; Single-pass type I membrane protein.; [Isoform A.2]: Cell membrane; Single-pass type I membrane protein.; [Isoform A.3]: Cell membrane; Single-pass type I membrane protein.; [Isoform B]: Secreted.; [Isoform B-delta-S2]: Secreted.
Tissue Specificity
Isoform A.1, isoform A.2 and isoform A.3 are differentially expressed between blood and mucosal myeloid cells. Isoform A.1, isoform A.2 and isoform A.3 are expressed in monocytes. Isoform A.1 and isoform A.2 are expressed in alveolar macrophages; however
Database Links

HGNC: 3608

OMIM: 147045

KEGG: hsa:2204

STRING: 9606.ENSP00000347714

UniGene: Hs.659872

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2026 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*